OliX Pharmaceuticals Secures KRW 110 Billion Investment from BOLD, L’Oréal Corporate Venture Capital Fund, and Weiss, U.S. Hedge Fund
Participation of both strategic partner and key global investor
Underlines the potential of OliX Pharmaceuticals’ siRNA platform
OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that it has raised approximately KRW 110 billion through a third-party allotment of newly issued common shares to strategic investors. The investment was jointly made by BOLD, L’Oréal’s corporate venture capital fund, and Weiss Asset Management LP, a U.S. asset management firm.
BOLD is L'Oréal’s venture investment arm that backs promising beauty brands, biotech, and tech companies, especially those with disruptive innovation potential. The U.S. asset manager is also a key global investor in OliX and participated in this round following its investment in August 2025.
